MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clbc.2013.08.012

Медицинская библиотека · Clinical breast cancer · 2013

Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer.

Campagnoli Carlo, Berrino Franco, Venturelli Elisabetta, Abbà Chiara, Biglia Nicoletta, Brucato Tiziana, Cogliati Patrizia, Danese Saverio, Donadio Michela, Zito Gianna, Pasanisi Patrizia

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

INTRODUCTION

Diabetic patients treated with metformin have a lower risk of developing BC or a better BC prognosis. Metformin might reduce cancer growth through direct antiproliferative effects or through indirect mechanisms, particularly the reduction of insulin. In a randomized study on nondiabetic BC patients in natural menopause with high testosterone levels, we observed a significant decrease in insulin and in testosterone levels with metformin 1500 mg/d compared with 1000 mg/d. We present the results of a new analysis of our study on the effect of metformin on the bioavailability of sex hormones.

PATIENTS AND

METHODS

One hundred twenty-four eligible women were initially invited to take metformin 500 mg/d for 3 months. The 108 women who completed the first 3 months continued the study using 1000 mg/d for 1 month. The women were then randomized into 2 groups, and, for the subsequent 5 months, 1 group increased the dose to 1500 mg/d, and the other group continued with 1000 mg/d.

RESULTS

Ninety-six women completed the study, 43 receiving metformin 1500 mg/day, and 53 receiving 1000 mg/day. The women receiving 1500 mg/d showed a greater and significant reduction of free testosterone (-29%) and estradiol (-38%), a borderline significant reduction of estrone and insulin-like growth factor-1, and a nonsignificant reduction of androstenedione. They also showed a nonsignificant increase of dehydroepiandrosterone sulfate.

CONCLUSION

Metformin does not interfere with the production of dehydroepiandrosterone sulfate. Besides, it decreases estradiol levels, basically through the reduction of testosterone. These hormonal changes might have clinical relevance.

Для цитирования: Campagnoli Carlo, Berrino Franco, Venturelli Elisabetta, Abbà Chiara, Biglia Nicoletta, Brucato Tiziana, Cogliati Patrizia, Danese Saverio, Donadio Michela, Zito Gianna, Pasanisi Patrizia. Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer.. Clinical breast cancer. 2013. DOI: 10.1016/j.clbc.2013.08.012.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.